Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators

Autor: Wojciech Zareba, James P. Daubert, Christopher A. Beck, David T. Huang, Jeffrey D. Alexis, Mary W. Brown, Kathryn Pyykkonen, Scott McNitt, David Oakes, Changyong Feng, Mehmet K. Aktas, Felix Ayala-Parades, Adrian Baranchuk, Marc Dubuc, Mark Haigney, Alexander Mazur, Craig A. McPherson, L. Brent Mitchell, Andrea Natale, Jonathan P. Piccini, Merritt Raitt, Mayer Y. Rashtian, Claudio Schuger, Stephen Winters, Seth J. Worley, Ohad Ziv, Arthur J. Moss, W. Zareba, K. Pyykkonen, A. Buttaccio, E. Perkins, D. DeGrey, S. Robertson, A.J. Moss, M. Brown, R. Lansing, A. Oberer, B. Polonsky, V. Ross, A. Papernov, S. Schleede, C. Beck, D. Oakes, C. Feng, S. McNitt S, W.J. Hall, A. Moss, J. Daubert, D. Huang, S. Winters, C. Schuger, M. Haigney, J. Piccini, J. Alexis, L. Chen, A. Miller, J.F. Richeson, S. Rosero, V. Kutyifa, A. Shah, G. Lamas, F. Cohn, F. Harrell, I. Piña, J. Poole, M. Sullivan, D. Lathrop, N. Geller, R. Boineau, J. Trondell, L. Cooper, E. Itturiaga, C. Gottlieb, S. Greer, C. Perzanowski, C. McPherson, C. Hedgepeth, C. Assal, T. Salam, I. Woollett, G. Tomassoni, F. Ayala-Paredes, A. Russo, S. Punnam, R. Sangrigoli, S. Sloan, S. Kutalek, A. Sun, D. Lustgarten, G. Monir, D. Haithcock, R. Sorrentino, D. Cannom, J. Kluger, S. Varanasi, M. Rashtian, F. Philippon, R. Berger, M. Mazzella, T. Lessmeier, J. Silver, S. Worley, M. Bernabei, D. Esberg, M. Dixon, P. LeLorier, Y. Greenberg, V. Essebag, G. Venkataraman, T. Shinn, M. Dubuc, G. Turitto, C. Henrikson, M. Mirro, M. Raitt, A. Baranchuk, G. O'Neill, E. Lockwood, M. Vloka, J. Hurwitz, R.H. Mead, P. Somasundarum, E. Aziz, E. Rashba, A. Budzikowski, M. Cox, A. Natale, E. Chung, O. Ziv, F. McGrew, K. Tamirisa, A. Greenspon, M. Estes, S. Taylor, R. Janardhanan, L.B. Mitchell, M. Burke, M. Attari, B. Mikaelian, S. Hsu, J. Conti, A. Mazur, S. Shorofsky, L. Rosenthal, S. Sakaguchi, D. Wolfe, G. Flaker, S. Saba, M. Aktas, P. Mason, A. Shalaby, D. Musat, R. Abraham, K. Ellenbogen, C. Fellows, N. Kavesh, G. Thomas, D. Hemsworth, B. Williamson

Publikováno v: Journal of the American College of Cardiology. 72:636-645

Background Ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a challenging problem in patients with implantable cardioverter-defibrillators (ICDs). Objectives This study aimed to determine whether ranolazine administration decreas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a3da108e14703d249a00ad70af08bb8
https://doi.org/10.1016/j.jacc.2018.04.086